Novel Regimens of Bedaquiline-Pyrazinamide Combined with Moxifloxacin, Rifabutin, Delamanid and/or OPC-167832 in Murine Tuberculosis Models-Reference-Cited by-同舟云学术

Novel Regimens of Bedaquiline-Pyrazinamide Combined with Moxifloxacin, Rifabutin, Delamanid and/or OPC-167832 in Murine Tuberculosis Models

Published:2022-04-19 Issue:4 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Tasneen Rokeya¹,Garcia Andrew¹,Converse Paul J.¹,Zimmerman Matthew D.²,Dartois Veronique²^ORCID,Kurbatova Ekaterina³,Vernon Andrew A.³,Carr Wendy³,Stout Jason E.⁴,Dooley Kelly E.¹^ORCID,Nuermberger Eric L.¹^ORCID

Affiliation:

1. Center for Tuberculosis Research, Johns Hopkins University, Baltimore, Maryland, USA

2. Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA

3. Centers for Disease Control and Prevention, Atlanta, Georgia, USA

4. Duke University, Durham, North Carolina, USA

Abstract

A recent landmark trial showed a 4-month regimen of rifapentine, pyrazinamide, moxifloxacin, and isoniazid (PZMH) to be noninferior to the 6-month standard of care. Here, two murine models of tuberculosis were used to test whether novel regimens replacing rifapentine and isoniazid with bedaquiline and another drug would maintain or increase the sterilizing activity of the regimen.

Funder

Westat

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.02398-21

Reference35 articles.

1. Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients

2. Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis

3. Bactericidal Potencies of New Regimens Are Not Predictive of Their Sterilizing Potencies in a Murine Model of Tuberculosis